1. Home
  2. SQNS vs KZIA Comparison

SQNS vs KZIA Comparison

Compare SQNS & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sequans Communications S.A.

SQNS

Sequans Communications S.A.

HOLD

Current Price

$5.32

Market Cap

85.3M

Sector

Technology

ML Signal

HOLD

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

HOLD

Current Price

$7.44

Market Cap

74.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SQNS
KZIA
Founded
2003
1994
Country
France
Australia
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
85.3M
74.4M
IPO Year
2011
1999

Fundamental Metrics

Financial Performance
Metric
SQNS
KZIA
Price
$5.32
$7.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$21.33
$17.67
AVG Volume (30 Days)
206.8K
255.5K
Earning Date
02-10-2026
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$31,534,000.00
$1,199,108.00
Revenue This Year
N/A
N/A
Revenue Next Year
$70.61
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.20
N/A
52 Week Low
$4.44
$2.86
52 Week High
$58.30
$17.40

Technical Indicators

Market Signals
Indicator
SQNS
KZIA
Relative Strength Index (RSI) 49.60 47.35
Support Level $5.13 $6.85
Resistance Level $5.50 $7.69
Average True Range (ATR) 0.27 0.70
MACD 0.07 0.17
Stochastic Oscillator 48.55 82.85

Price Performance

Historical Comparison
SQNS
KZIA

About SQNS Sequans Communications S.A.

Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its offer 5G/4G chips and modules fully optimized for non-smartphone devices. The company covers applications such as smart mobility and logistics, smart utility meters, smart cities, smart industries, e-health and wellness, and smart homes to name few. The Company has one operating segment, which is the design and marketing of semiconductor components for cellular wireless systems. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Share on Social Networks: